ReviewInternational journal of molecular sciences2022
Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Hypophosphataemia following iron infusion: a narrative review of an increasingly recognised complication.Internal medicine journal · 2026Review
- Emerging paradigms in nanostructured targeted drug delivery systems.Discover nano · 2026Review
- Stability Assessment of Intravenous Iron-Carbohydrate Complexes in Commercial All-in-One Parenteral Nutrition: Potential for Therapeutic Iron Dose Admixing.Pharmaceutics · 2026Article
- Prevalence, predictors, and natural history of hypophosphatemia following iron infusion.JBMR plus · 2025Article
- Challenging Traditional ADME Assumptions for Physiologically Based Pharmacokinetic Models for Intravenous Administration of Iron-Carbohydrate Nanomedicines: Potential Utility of Gold Nanoparticle Models as a Roadmap.Clinical pharmacokinetics · 2025Review
- Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency.British journal of haematology · 2025Article
- Nanovaccines in gastrointestinal cancers.Frontiers in immunology · 2025Review
- How do nanoparticle properties shape pharmacokinetics and pharmacodynamics? A mechanistic review.Frontiers in pharmacology · 2025Review
- Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway.European heart journal · 2024Observational
- Article
- Nanosimilars: A Scientific or A Regulatory Debate?The AAPS journal · 2024Review
- Iron deficiency and supplementation in heart failure.Nature reviews. Cardiology · 2024Review
- Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.Advanced healthcare materials · 2023Article
- Review
- Probing Subcellular Iron Availability with Genetically Encoded Nitric Oxide Biosensors.Biosensors · 2022Article
- Hypersensitivity to Intravenous Iron Preparations.Children (Basel, Switzerland) · 2022Review
- Correction: Funk et al. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.International journal of molecular sciences · 2022Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Un-complexed polynuclear ferric oxyhydroxide cannot be administered safely or effectively to patients. When polynuclear iron cores are formed with carbohydrates of various structures, stable complexes with surface carbohydrates driven by multiple interacting sites and forces are formed. These complexes deliver iron in a usable form to the body while avoiding the serious adverse effects of un-complexed forms of iron, such as polynuclear ferric oxyhydroxide. The rate and extent of plasma clearance and tissue biodistribution is variable among the commercially available iron-carbohydrate complexes and is driven principally by the surface characteristics of the complexes which dictate macrophage opsonization. The surface chemistry differences between the iron-carbohydrate complexes results in significant differences in in vivo pharmacokinetic and pharmacodynamic profiles as well as adverse event profiles, demonstrating that the entire iron-carbohydrate complex furnishes the pharmacologic action for these complex products. Currently available physicochemical characterization methods have limitations in biorelevant matrices resulting in challenges in defining critical quality attributes for surface characteristics for this class of complex nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.